Toward understanding their redundancies and interactions in hemostasis and thrombosis, we examined the roles of thrombin receptors (protease-activated receptors, PARs) and the ADP receptor P2RY12 (purinergic receptor P2Y G protein-coupled 12) in human and mouse platelets ex vivo and in mouse models. Par3 −/− mice, which lack platelet thrombin responses, showed still better protection. Our data suggest that (i) the level of thrombin driving platelet activation and carotid thrombosis was low at low levels of arterial injury and increased along with the contribution of thrombin-independent pathways of platelet activation with increasing levels of injury; (ii) although P2ry12 acts downstream of PARs to amplify platelet responses to thrombin ex vivo, P2ry12 functioned in thrombin/PAR-independent pathways in our in vivo models; and (iii) P2ry12 signaling was more important than PAR signaling in hemostasis models; the converse was noted for arterial thrombosis models. These results make predictions being tested by ongoing human trials and suggest hypotheses for new antithrombotic strategies.
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+/− mice, restored it. Par4 −/− mice, which lack platelet thrombin responses, showed still better protection. Our data suggest that (i) the level of thrombin driving platelet activation and carotid thrombosis was low at low levels of arterial injury and increased along with the contribution of thrombin-independent pathways of platelet activation with increasing levels of injury; (ii) although P2ry12 acts downstream of PARs to amplify platelet responses to thrombin ex vivo, P2ry12 functioned in thrombin/PAR-independent pathways in our in vivo models; and (iii) P2ry12 signaling was more important than PAR signaling in hemostasis models; the converse was noted for arterial thrombosis models. These results make predictions being tested by ongoing human trials and suggest hypotheses for new antithrombotic strategies.
vorapaxar | acute coronary syndromes | myocardial infarction | stroke | SCH530348 P latelet activation at sites of vascular injury contributes to hemostasis and to thrombi that cause myocardial infarction and a subset of strokes. Multiple extracellular cues activate platelets via distinct receptors, individual activators often act via more than one receptor, and platelets themselves release agonists that amplify and sustain platelet activation (1) . Current drugs that inhibit platelet activation prevent or interrupt myocardial infarction and thromboembolic strokes at the cost of bleeding (2) , and such drugs are increasingly used in combination in part because unproven drugs are often first tested on top of established therapies (3, 4) . Illuminating the relative importance of different platelet activators and their redundancies and interactions in vivo is needed to better understand hemostasis and thrombosis and to better rationalize the development of antithrombotic therapies. We examined these issues for two key platelet activators, thrombin and ADP.
Thrombin, the effector protease of the coagulation cascade, is arguably the most potent platelet activator (5) . Thrombin triggers human platelet activation via two protease-activated receptors (PARs), PAR1 and PAR4 (6, 7) . Ablation of PAR1 signaling impairs platelet activation by low concentrations of thrombin. Responses to high concentrations of thrombin seen in PAR1-inhibited human platelets are PAR4-dependent (7) . When and where platelet responses to low vs. high concentrations of thrombin are important in hemostasis and thrombosis remains to be determined and is of immediate clinical relevance. A PAR1 antagonist SCH530348 (vorapaxar) is in Phase 3 clinical trials for treatment of acute coronary syndromes and for secondary prevention of myocardial infarction and stroke (3, 4) .
ADP is secreted by platelets in response to multiple extracellular signals, including thrombin acting via PARs (8) . Secreted ADP acts in an autocrine/paracrine fashion on the platelet ADP receptor P2RY12 (purinergic receptor P2Y G protein-coupled 12) to amplify and sustain platelet activation (9) . The relative importance of P2RY12 vs. PARs and the extent to which they make redundant vs. independent contributions in hemostasis and thrombosis is not known. Moreover, clopidogrel and related drugs that irreversibly block P2RY12 function prevent and treat arterial thrombosis but cause bleeding (2, 10) , and PAR1 antagonists are being studied as an adjunct to standard antithrombotic treatment that includes P2RY12 inhibition (3, 4) . How inhibition of these key platelet-activating pathways might interact is uncertain.
We used mouse models and studies of mouse and human platelet function ex vivo to characterize the importance of different levels of thrombin and ADP signaling and their interactions in hemostasis and thrombosis. Our results suggest three hypotheses regarding antithrombotic therapy in humans: (i) PAR1 inhibition alone might provide some protection against arterial thrombosis without significant hemostatic cost; (ii) addition of PAR1 inhibition to standard P2RY12 inhibition might provide increased protection with relatively little increase in bleeding; and (iii) combining PAR4 inhibition with PAR1 inhibition might provide still more protection without a further substantial increase in bleeding. Hypothesis 2 is being tested in ongoing clinical trials (3, 4) . A positive result would suggest at least some predictive value of these mouse models and encourage exploration of hypotheses 1 and 3.
Results
To provide a foundation for in vivo studies in mice and generation of hypotheses potentially relevant to humans, we compared thrombin and ADP responses in mutant and inhibitor-treated mouse and human platelets ex vivo. Endpoints included activation of the integrin α IIb β 3 , which binds fibrinogen to drive platelet aggregation, and surface expression of P-selectin, which reflects α-granule secretion and supports interactions with endothelial cells and leukocytes (11, 12) .
Thrombin Responses in PAR Mutant Mouse Platelets and PAR1-Inhibited Human Platelets. Human platelets use PAR1 and PAR4 to sense thrombin (7); mouse platelets use Par3 and Par4 (13) . PAR1 and Par3 are required for normal responsiveness to low concentrations of thrombin in human and mouse platelets, respectively, but unlike human PAR1, mouse Par3 does not itself mediate transmembrane signaling. Instead, Par3 binds thrombin and serves as a cofactor for Par4 activation at low thrombin concentrations (14, 15) ; in accord, Par4 −/− mouse platelets do not respond to even high concentrations of thrombin (15) .
The EC 50 for thrombin-induced α IIb β 3 activation was 0.10 ± 0.08, 0.20 ± 0.05, and 1.5 ± 0.7 nM in wild-type, Par4 +/− , and Par3 −/− mouse platelets, and maximal responses were 102 ± 9, 85 ± 10, and 99 ± 11%, respectively (Fig. 1A) . Similar results were noted when P-selectin mobilization was used as an endpoint (Fig. S1B) , and Par4 −/− platelets showed no responses to thrombin as expected (Fig. S1 E and F) .
In human platelets, the PAR1 antagonist SCH530348 completely blocked responses to the PAR1 agonist SFLLRN, as expected (16) , and caused three-and sevenfold increases in the EC 50 for thrombin-induced α IIb β 3 activation and P-selectin display, respectively, similar to (but somewhat less than) the increases in EC 50 seen in Par3 −/− mouse platelets ( Fig. 1 A and B and Fig. S1 A-D). Maximal α IIb β 3 activation was decreased by ∼20%, similar to that in Par4 +/− mouse platelets; maximal Pselectin response was unchanged. These data are consistent with the model that Par3 −/− mouse and SCH530348-treated human platelets rely on their respective PAR4 homologs for thrombin signaling, and with the notion that alterations in platelet responses to thrombin in Par3 −/− mice and SCH530348-treated humans might be similar.
Thrombin Responses in Platelets with Altered P2RY12 Function. Addition of the adenine nucleotide-degrading enzyme apyrase, prior in vivo treatment with high-dose clopidogrel, or P2ry12 deficiency virtually abolished responses to ADP, increased the EC 50 for thrombin-induced α IIb β 3 activation ∼10-fold, and reduced maximal responses to thrombin 30% or more in both human and mouse platelets ( Fig. 1 C and D and Figs. S1 A-F and S2 A-C). The relative change in thrombin responses in Par4 +/− and Par3 −/− compared with wild-type platelets persisted in the presence of apyrase (Fig. S1 A and B) . Thus, complete ablation of P2RY12 function supported the view that ADP signaling amplifies platelet responses to PAR activation (17, 18) . However, the standard human dose of clopidogrel (75 mg daily) irreversibly blocks only about half of P2RY12 on human platelets (19) , mimicking the reduction expected in P2ry12 +/− mouse platelets. Maximal α IIb β 3 activation by ADP decreased from 65 ± 13% of the maximal thrombin response in wild-type to 49 ± 13% in P2ry12 +/− platelets, and EC 50 increased from 0.59 to 0.82 μM (Fig. 1D) . Such partial reductions in ADP responsiveness had only a small effect on thrombin responses in PAR wild-type platelets and no detectable effect in Par4 +/− and Par3 −/− platelets unless exogenous ADP was added (Fig. S3) . Thus, based on effects of altered P2ry12 function on thrombin responses, our ex vivo studies suggested that combining P2ry12 +/− with Par3 −/− or Par4 +/− genotypes should not produce additive or synergistic effects in vivo. However, subsequent in vivo studies found exactly such effects. Given the concentration-response data in Fig. 1A , the greater protection of Par3 −/− compared with Par4 +/− mice at 4% FeCl 3 suggests that the effective concentration of thrombin operating on mouse platelets may be relatively low at this level of injury.
Decreased protection in Par3
−/− and Par4 +/− mice but continued full protection in Par4 −/− mice at 8% FeCl 3 suggests that a higher level of thrombin may operate at this higher level of injury and/or that a low level of thrombin signaling becomes sufficient to support thrombosis as injury increases and other mediators come into play. The decreased protection of Par4 −/− mice at 20 vs. 8% FeCl 3 suggests that mechanisms independent of thrombin signaling in platelets become sufficient to cause thrombotic occlusion as the level of injury increases.
We next examined interactions between ADP/P2ry12 and thrombin/PAR signaling ( Fig. 3 and Fig. S5 ). At 20% FeCl 3 , carotids in wild-type, P2ry12 ). Similar results were obtained when high-dose clopidogrel rather than P2ry12 deficiency was employed (Fig. S6) . The strong effect of decreasing P2ry12 function and platelet responsiveness to ADP in Par4 −/− mice, which lack thrombin signaling in platelets, shows that ADP signaling via P2ry12 functions in a pathway independent of thrombin signaling via PARs in this model.
To probe interactions at levels of inhibition that better mimic those operating in humans treated with P2RY12 and PAR1 antagonists, we next compared P2ry12 +/− , Par3 (Fig. S3) is consistent with the view that thrombin and ADP signaling make independent contributions in this model, and the effects of increasing FeCl 3 injury suggest that contributions from both thrombin-dependent and thrombin-independent platelet activation increase with increasing vascular damage. To further assess responses to hemostatic challenges, we first measured tail bleeding time and blood loss (Fig. 4) . Par4 and P2ry12 genotypes each affected tail bleeding. Mean bleeding times and blood loss in wild-type, Par4 +/− , and Par4 −/− mice were 150, 198, and 486 s and 0.07, 0.11, and 1.4 arbitrary units (AU), respectively (Fig. 4 A and B) . Mean bleeding time and blood loss in P2ry12 +/− mice were 253 s and 0.38 AU. Bleeding times in P2ry12 −/− mice reliably reached 600 s, the protocol maximum, and blood loss exceeded 2.5 AU. Par4
−/− double knockouts showed a further significant increase in blood loss (Fig. 4B) (P < 0.0001). Treatment of PAR mutant mice with high-dose clopidogrel increased bleeding like adding P2ry12 deficiency (Fig. S7) . Thus, PARs and P2ry12 made significant and at least partially independent contributions in this hemostasis model, with P2ry12 appearing to have the greater role. The substantial effect of combining partial decreases in thrombin and ADP signaling seen in the arterial thrombosis model (Fig. 3 B and C and Fig. S5 B and C) was not apparent in the tail-bleeding assay (Fig. 4 A, B, D , and E). +/− mice again had a modest increase, and there was no significant interaction between the genotypes (Fig. 4F) .
Taken together, results from the tail and surgical bleeding assays suggest that normal hemostasis requires some thrombin signaling. The contrast between the moderate hemostatic defect in Par4 −/− mice and the absence of significant bleeding in Par3 −/− mice suggests that the concentration of thrombin that activates platelets in these models may be relatively high [such that the right-shift in the concentration response to thrombin in Par3 −/− platelets (Fig. 1A) is unimportant] and/or that a low level of thrombin signaling is sufficient. The relatively large effects of P2ry12 deficiency even in Par4 −/− mice suggests that pathways independent of thrombin signaling play a key role in P2ry12 activation and in hemostasis in these models.
Comparison of the Effects of Different Genotypes on Thrombosis vs.
Hemostasis. To facilitate comparison of the effects of different levels of inhibition of thrombin and ADP signaling on thrombosis vs. hemostasis, we generated X-Y plots of indices of protection against thrombosis vs. impaired hemostasis for each genotype. :P2ry12 −/− mice showed significant protection against thrombosis and at a cost of substantially impaired hemostasis (Fig. 5C and Figs . S8 E and F and S9 E and F). Par4 −/− :P2ry12 +/− mice showed modest protection, with impairment of hemostasis comparable to that seen in Par4 −/− mice. For all levels of injury and endpoints, points representing P2ry12 +/− and P2ry12 −/− mice were usually on or below the regression line, but points representing Par3 −/− and Par4 −/− mice were almost always above it, consistent with ADP signaling playing a relatively more important role in hemostasis and PAR signaling a more important role in thrombosis in these models. 
Discussion
Defining the roles, redundancies, and interactions of distinct platelet-activating signals in vivo is critical for understanding hemostasis and thrombosis. Studies to address these issues for thrombin and ADP are timely. The platelet ADP receptor P2RY12 is the target of the widely-used antithrombotic drug clopidogrel and related drugs (10, 20, 21) , and the antagonist of the platelet thrombin receptor PAR1, SCH530348, is in Phase 3 clinical trials as an adjunct to standard therapy that includes clopidogrel (3, 4) . We examined the roles of thrombin and ADP signaling in platelets in mouse models of hemostasis and thrombosis, probing effects of partial decreases in P2ry12 signaling relevant to what can be safely achieved in humans, together with partial and complete knockout of PAR function relevant to current and perhaps future clinical trials. Recognizing mouse-human differences in platelet receptors (and trying to accommodate them), differences between FeCl 3 -induced injury of normal arteries and plaque rupture, and the limitations of hemostasis models, we develop hypotheses regarding human hemostasis and thrombosis below. One hypothesis is currently being tested in human trials, the results of which may support or discourage exploration of the other model-based predictions described. Our results support an important role for thrombin signaling in platelets in a model of arterial thrombosis. Furthermore, a low level of thrombin appears to operate at low levels of FeCl 3 injury, and both the level of thrombin operating and the importance of thrombin-independent platelet-activating pathways increase with increasing arterial injury. Results in our hemostasis models most closely resembled the high-injury thrombosis model. The lack of bleeding in Par3 −/− mice compared with Par4 −/− mice in the hemostasis models is consistent with a relatively high level of thrombin driving platelet activation in these models, a low level of thrombin signaling being sufficient, and/or pathways independent of thrombin-induced platelet activation playing a major role.
Although thrombin triggers platelet secretion of ADP and P2ry12 signaling, our results strongly suggest that P2ry12 acts in pathways independent of PARs and thrombin signaling in our arterial thrombosis and hemostasis models. The observation that superimposing P2ry12 deficiency on Par4 deficiency increased protection against FeCl 3 -induced carotid artery thrombosis, as well as tail and surgical bleeding, implies that ADP/P2ry12 signaling was not simply functioning downstream of thrombin signaling. Similarly, the observation that P2ry12 heterozygosity decreased ADP responses without decreasing the thrombin responses in Par4 +/− and Par3 −/− platelets suggests that the added thrombosis protection associated with combining P2ry12 heterozygosity with Par4 heterozygosity or Par3 deficiency was probably a result of blunting a contribution of ADP signaling in a thrombin-independent pathway. Collagen-induced platelet responses are ADP-dependent (22) , indeed, more so than responses to thrombin (Fig. S2 C vs. E) . Thus, collagen-induced platelet activation is a candidate for a P2ry12-dependent, PARindependent pathway that contributes to thrombosis and hemostasis in these models.
Par3 −/− mouse platelets and PAR1-inhibited human platelets both rely on PAR4 to mediate thrombin responses, and both showed a right shift in the concentration response to thrombin for α IIb β 3 activation, P-selectin display, and other endpoints ( Fig.  1 and refs. 7 and 13 ). In the context of our results in mouse models, these similarities raise interesting questions. The level of platelet activation triggered by plaque rupture appears to range from below the level required for formation of symptomatic thrombi, through an intermediate level sufficient for stuttering thrombus formation that causes unstable angina and non-ST segment elevation myocardial infarction, to a high level sufficient for rapid and complete thrombotic occlusion and transmural myocardial infarction (23, 24) . Even the modest decrease in thrombin signaling obtained in Par3 −/− mouse platelets raised the level of injury required to drive arterial occlusion in our models. Might the similar decrease in thrombin signaling that occurs in PAR1-inhibited human platelets be sufficient to increase the degree of injury required to drive thrombotic arterial occlusion in humans? The observation that Par3 −/− mice showed more protection than P2ry12 +/− mice with less bleeding raises the possibility that the risk and benefit associated with PAR1 inhibition might compare favorably with that of standard clopidogrel therapy. Decreased P2ry12 function generally had a greater effect on hemostasis than did decreased PAR function in our models, and the marked increase in hemostatic impairment associated with complete P2ry12 deficiency compared with P2ry12 heterozygosity in our mouse models (Fig. 4) may be in accord with clinical studies in which higher levels of P2RY12 occupancy resulted in increased serious bleeding, together with increased protection against arterial thrombosis (10) . Current clinical trials are testing PAR1 inhibition in secondary prevention of myocardial infarction and stroke in a population that will likely include many patients treated with clopidogrel or aspirin (4). If efficacy for PAR1 inhibition is established, and depending upon the incidence of bleeding in these studies, our results suggest that PAR1 might be explored as a stand-alone therapy, or perhaps as an adjunct to aspirin alone, for secondary prevention in lower-risk groups in which the bleeding risk associated with clopidogrel treatment is unacceptable (2) .
The observation that combined partial inhibition of thrombin and ADP signaling in Par3 incremental protection against arterial thrombosis, perhaps with only a minor cost in bleeding. As noted above, this hypothesis is already being tested (3, 4) ; a positive result would support further exploration of the other hypotheses regarding stand-alone PAR1 inhibition (discussed above) and combined PAR1-PAR4 (discussed below) generated from our studies in models.
The observation that complete ablation of thrombin-induced platelet activation in Par4 −/− mice conferred substantially more protection against arterial thrombosis than that seen in Par3 −/− : P2ry12 +/− mice without a significant increase in tail blood loss or surgical bleeding suggests that complete ablation of thrombin signaling in human platelets, which would require dual PAR1-PAR4 inhibition (7), might provide increased protection against arterial thrombosis at reasonable hemostatic cost. Such an approach might be explored in high-risk groups or high-injury settings, such as stent placement. If ongoing trials reveal that a safe PAR1 antagonist is in hand (3, 4) , dual PAR1-PAR4 inhibition may be worthy of further preclinical and perhaps clinical exploration.
Materials and Methods
See SI Materials and Methods for detailed discussion. Mice. All studies were performed blind to genotype and treatment. University of California San Francisco's Institutional Animal Care and Use Committee approved the protocols. Generation of Par3, Par4, and P2ry12 mutants has been described (13, 15, 25) . All mice had been backcrossed seven or more generations into a C57BL/6 background. All studies compared littermates, except as noted for the wild-type group in Fig. 3A .
Ex Vivo Studies of Platelet Function. Washed mouse and human platelets were prepared and flow cytometric assays of P-selectin display and α IIb β 3 activation were performed using standard techniques (SI Materials and Methods). SCH530348 (16) was synthesized and characterized as described in SI Materials and Methods. For clopidogrel treatment, mice were dosed with 30-mg/ kg drug or water by gavage 24 and 3 h before blood collection.
In Vivo Studies of Platelet Function. Carotid thrombosis assays (26) used 8-to 14-wk-old mice. Tail bleeding times and blood loss were examined using standard techniques (SI Materials and Methods). A semiquantitative measure of bleeding into the surgical field during the carotid thrombosis assay was devised. The field was dabbed with cotton-tipped swabs (Fisherbrand, catalog no. 23-400-118), tip first, to keep the field bloodless. The length of the blood-saturated portion of each swab was determined at the end of the assay. The total length for each mouse was scored: No blood loss = 0, <1 swab length = 1, 1 to 3 swab lengths = 2, and >3 swab lengths = 3. Despite the semiquantitative nature of this measure, genotype-and treatmentdependent differences that tracked with the other hemostasis assays were found.
Statistical Analysis. Kaplan-Meier-type data were compared by Log Rank test; endpoints were compared by χ 2 . Other comparisons used two-way analysis of variance followed by the Holm-Sidak test or t test for multiple comparisons with a Bonferroni correction.
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